IceCure Medical Ltd. (NASDAQ: ICCM) Earnings Report Highlights

Core Insights - IceCure Medical Ltd. specializes in minimally-invasive cryoablation technology for low-risk breast cancer treatment, providing an alternative to traditional surgical methods [1] - The company is expanding its market presence in the U.S. and internationally following FDA marketing authorization for its ProSense cryoablation system [1] Financial Performance - For the earnings report on November 19, 2025, the company reported an EPS of -$0.056, which was below the estimated EPS of -$0.05 [2][6] - Revenue for the same period was $725,000, surpassing the estimated $714,000, indicating stronger-than-expected sales performance [2][6] Market Demand and Growth Potential - The earnings call highlighted increasing demand for ICCM's ProSense systems, with expectations for acceleration in 2026, targeting a U.S. patient population of approximately 200,000 [3] Financial Metrics - The company has a price-to-sales ratio of 17.31, suggesting that investors are willing to pay a premium for its sales [4] - The enterprise value to sales ratio stands at 16.23, indicating similar high expectations from an enterprise perspective [4] - ICCM's debt-to-equity ratio is 0.82, reflecting a moderate level of debt management [5] - A current ratio of 1.18 indicates a reasonable level of short-term financial health, with current assets slightly exceeding current liabilities [5]